Lite Strategy (LITS) Other Non-Current Assets (2024 - 2026)

Lite Strategy (LITS) posted quarterly Other Non-Current Assets of $678000.0 for Q1 2026, down 3.83% quarter-over-quarter from $705000.0 in Q4 2025.

Lite Strategy (LITS) Other Non-Current Assets (2024 - 2026) Analysis & Trends

Lite Strategy's Other Non-Current Assets history runs 3 years deep, the most recent figure standing at $678000.0 for Q1 2026.

In Q1 2026, Other Non-Current Assets changed N/A year-over-year to $678000.0; the TTM figure through Mar 2026 stood at $678000.0 (changed N/A YoY), while the FY2024 annual figure was $263000.0, changed N/A from the prior year.
Other Non-Current Assets for Q1 2026 stood at $678000.0, down from $705000.0 in the prior quarter.
The five-year high for Other Non-Current Assets was $732000.0 in Q3 2025, with the low at $263000.0 in Q2 2024.
The 3-year median for Other Non-Current Assets is $678000.0 (2026), against an average of $528200.0.
Peak annual rise in Other Non-Current Assets reached 178.33% in 2025, while the deepest fall reached 178.33% in 2025.
Lite Strategy's Other Non-Current Assets stood at $263000.0 in 2024, then soared by 168.06% to $705000.0 in 2025, then slipped by 3.83% to $678000.0 in 2026.
Business Quant data shows LITS's Other Non-Current Assets at $678000.0 in Q1 2026, $705000.0 in Q4 2025, and $732000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Other Non-Current Assets (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	1.25 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	2.31 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	124.00 Mn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	618.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	109.58 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	65.13 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	202.31 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	104.44 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	62.96 Mn
10	Lite Strategy	35.71 Mn	28.17 Mn	-	678,000.00

Download Data